221 related articles for article (PubMed ID: 9736988)
1. [Is skeletal alkaline phosphatase a valid staging marker in detection of osteoblastic skeletal metastases of prostate carcinoma?].
Wirtz DC; Wolff JM; Ittel TH; Jakse G; Niethard FU
Z Orthop Ihre Grenzgeb; 1998; 136(3):255-9. PubMed ID: 9736988
[TBL] [Abstract][Full Text] [Related]
2. Metastatic workup of patients with prostate cancer employing alkaline phosphatase and skeletal alkaline phosphatase.
Wolff JM; Ittel TH; Borchers H; Boekels O; Jakse G
Anticancer Res; 1999; 19(4A):2653-5. PubMed ID: 10470213
[TBL] [Abstract][Full Text] [Related]
3. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
Morote J; Lorente JA; Encabo G
Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
[TBL] [Abstract][Full Text] [Related]
4. Metastatic workup of patients with prostate cancer employing skeletal alkaline phosphatase.
Wolff JM; Ittel TH; Boeckmann W; Habib FK; Jakse G
Anticancer Res; 1997; 17(4B):2995-7. PubMed ID: 9329584
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer.
Lorente JA; Morote J; Raventos C; Encabo G; Valenzuela H
J Urol; 1996 Apr; 155(4):1348-51. PubMed ID: 8632571
[TBL] [Abstract][Full Text] [Related]
6. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
Xie W; Nakabayashi M; Regan MM; Oh WK
Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of skeletal alkaline phosphatase and prostate-specific antigen in the diagnosis of bone metastasis in cancer of the prostate.
Wolff JM; Ittel T; Borchers H; Brauers A; Jakse G
Urol Int; 1998 Oct; 61(1):12-6. PubMed ID: 9792976
[TBL] [Abstract][Full Text] [Related]
8. [Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group].
Taue R; Kanayama H; Kagawa S
Hinyokika Kiyo; 1999 Oct; 45(10):681-5. PubMed ID: 10586358
[TBL] [Abstract][Full Text] [Related]
9. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
10. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
[TBL] [Abstract][Full Text] [Related]
11. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
13. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers.
Leeming DJ; Hegele A; Byrjalsen I; Hofmann R; Qvist P; Karsdal MA; Schrader AJ; Wagner R; Olbert P
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1269-76. PubMed ID: 18483350
[TBL] [Abstract][Full Text] [Related]
14. Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma.
Klepzig M; Jonas D; Oremek GM
Anticancer Res; 2009 Feb; 29(2):671-3. PubMed ID: 19331219
[TBL] [Abstract][Full Text] [Related]
15. Skeletal alkaline phosphatase in the metastatic workup of patients with prostate cancer.
Wolff JM; Ittel T; Boeckmann W; Reinike T; Habib FK; Jakse G
Eur Urol; 1996; 30(3):302-6. PubMed ID: 8931961
[TBL] [Abstract][Full Text] [Related]
16. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state.
Zissimopoulos A; Bantis A; Sountoulides P; Giannakopoulos S; Kalaitzis C; Agelonidou E; Touloupidis S
Hell J Nucl Med; 2009; 12(3):234-7. PubMed ID: 19936334
[TBL] [Abstract][Full Text] [Related]
18. Prostate specific antigen in the diagnosis and staging of prostate cancer.
Jung P; Wolff JM; Mattelaer P; Jakse G
Acta Urol Belg; 1996 Sep; 64(3):1-6. PubMed ID: 8946774
[TBL] [Abstract][Full Text] [Related]
19. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
20. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
